Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by Infinityon Dec 20, 2023 6:21am
277 Views
Post# 35793252

EOY

EOYIt would be nice if RDW and Dr. Mandel put out a Year End Recap for their investors.  Touching on
1. The progress of Talks with FDA for BTD or Pre-BTD
2.  Touch on other indications like NSCLC and GBM studies that are in the pipeline.
3.  What is happening with Vaccine research.  Has it completed the animal testing stage.
4.  What is being done to speed up the patient enrollment for the current cliniccal study sites.
5.  Perhaps out line the  Non Dilutive financing that RDW indicated in one of the recent interviews.
6.  Finally talks on JV  or some sort of joint development with big pharma.  Most of it will be confidential.   He can certainly describethe  progress without naming the big Pharma or JV partners.
7.  Financial forecast from the CFO would be greatly appreciated.


<< Previous
Bullboard Posts
Next >>